Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Breztri Aerosphere is a prescription inhalation aerosol containing budesonide, glycopyrrolate, and formoterol fumarate. Budesonide is an inhaled corticosteroid, glycopyrrolate is an anticholinergic, and formoterol is a long-acting beta2-adrenergic agonist. It is approved for maintenance treatment of chronic obstructive pulmonary disease in adults and asthma in patients age 12 and older.
read more about breztri aerosphere ...Budesonide reduces inflammatory activity through glucocorticoid receptors. Glycopyrrolate blocks muscarinic receptors that cause airway smooth muscle contraction. Formoterol stimulates beta2-adrenergic receptors and relaxes airway smooth muscle. Together, the three components combine anti-inflammatory activity with two different forms of long-acting bronchodilation.
Breztri Aerosphere is approved for maintenance treatment of chronic obstructive pulmonary disease in adults. As of April 2026, the U.S. label also includes maintenance treatment of asthma in adults and patients age 12 and older. It is not indicated for rapid relief of acute bronchospasm.
Adults with chronic obstructive pulmonary disease use two inhalations of the 160 mcg budesonide, 9 mcg glycopyrrolate, and 4.8 mcg formoterol strength twice daily. Asthma in patients age 12 and older uses two inhalations of the 160 mcg, 18 mcg, and 4.8 mcg strength twice daily. The mouth is rinsed after each dose.
Breztri Aerosphere can cause oral candidiasis, pneumonia, adrenal effects, reduced bone mineral density, paradoxical bronchospasm, cardiovascular effects, cataracts, glaucoma, urinary retention, low potassium, and high blood glucose. In pediatric asthma treatment, inhaled corticosteroids can reduce growth velocity. Sudden breathing attacks require a short-acting bronchodilator.
Breztri Aerosphere contains budesonide, glycopyrrolate, and formoterol fumarate.
Yes. The U.S. label includes maintenance treatment of asthma in patients age 12 and older.
The labeled regimen uses two inhalations twice daily for both chronic obstructive pulmonary disease and asthma.
No. It is not indicated for rapid relief of acute bronchospasm.
BREZTRI AEROSPHERE (budesonide, glycopyrrolate, and formoterol fumarate) Prescribing Information. https://www.azpicentral.com/pi.html?product=breztri. Date Accessed September 16, 2026.
BREZTRI Approved in the US for Asthma as First and Only Triple Therapy for Patients 12 Years of Age and Older. AstraZeneca. https://www.astrazeneca-us.com/media/press-releases/2026/BREZTRI-approved-in-the-US-for-asthma-as-first-and-only-triple-therapy-for-patients-12-years-of-age-and-older.html. Date Accessed September 16, 2026.
BREZTRI COPD & Asthma Safety Information & Side Effects. https://www.breztri.com/safety-information. Date Accessed September 16, 2026.
DailyMed - BREZTRI (budesonide, glycopyrrolate, and formoterol fumarate) aerosol, metered. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c. Date Accessed September 16, 2026.
FDA Label - BREZTRI AEROSPHERE (budesonide, glycopyrrolate, and formoterol fumarate) Inhalation Aerosol. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212122s009lbl.pdf. Date Accessed September 16, 2026.